Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era

Journal of Clinical Oncology

Volumn 28, Issue 6, 2010, Pages 1038-1046

  Evens, Andrew M ^a   David, Kevin A ^a   Helenowski, Irene ^a   Nelson, Beverly ^a   Kaufman, Dixon ^a   Kircher, Sheetal M ^a   Gimelfarb, Alla ^a   Hattersley, Elise ^a   Mauro, Lauren A ^a   Jovanovic, Borko ^a   Chadburn, Amy ^a   Stiff, Patrick ^a   Winter, Jane N ^a   Mehta, Jayesh ^a   Van Besien, Koen ^a   Gregory, Stephanie ^a   Gordon, Leo I ^a   Shammo, Jamile M ^a   Smith, Scott E ^a   Smith, Sonali M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CARDIOMYOPATHY; CELLULITIS; DISEASE COURSE; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; HEART TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE PERFORATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTICENTER STUDY; ORGAN TRANSPLANTATION; OSTEOMYELITIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; T CELL LYMPHOMA; TUMOR LYSIS SYNDROME; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77949902071     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4961     Document Type: Article

References (44)

1. Penn I, Hammond W, Brettschneider L, Starzl TE: Malignant lymphomas in transplantation patients. Transplant Proc 1:106-112, 1969
2. Opelz G, Dohler B: Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4:222-230, 2004 (Pubitemid 38248525)
3. Smith JM, Rudser K, Gillen D, et al: Risk of lymphoma after renal transplantation varies with time: An analysis of the United States Renal Data System. Transplantation 81:175-180, 2006
4. Walker RC, Paya CV, Marshall WF, et al: Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 14:214-221, 1995
5. Knight J, Tsodikov A, Cibrik D, et al: Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 27:3354-3362, 2009
6. Trofe J, Buell JF, Beebe TM, et al: Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 5:775-780, 2005 (Pubitemid 40461287)
7. Faull RJ, Hollett P, McDonald SP: Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 80:193-197, 2005 (Pubitemid 41061675)
8. Dotti G, Fiocchi R, Motta T, et al: Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 74:1095-1102, 2002 (Pubitemid 35216102)
9. Ghobrial IM, Habermann TM, Maurer MJ, et al: Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 23:7574-7582, 2005 (Pubitemid 46291821)
10. Ghobrial IM, Habermann TM, Ristow KM, et al: Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 46:191-196, 2005 (Pubitemid 40185948)
11. Leblond V, Dhedin N, Mamzer Bruneel MF, et al: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 19:772-778, 2001 (Pubitemid 32119092)
12. Nelson BP, Nalesnik MA, Bahler DW, et al: Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: A distinct entity? Am J Surg Pathol 24:375-385, 2000 (Pubitemid 30127473)
13. Starzl TE, Nalesnik MA, Porter KA, et al: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583-587, 1984 (Pubitemid 14156511)
14. Swinnen LJ, Mullen GM, Carr TJ, et al: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:3333-3340, 1995
15. Feugier P, Van Hoof A, Sebban C, et al: Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
16. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
17. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007
18. Choquet S, Leblond V, Herbrecht R, et al: Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 107:3053-3057, 2006
19. González-Barca E, Domingo-Domenech E, Capote FJ, et al: Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica 92:1489-1494, 2007 (Pubitemid 350144124)
20. Taylor AL, Bowles KM, Callaghan CJ, et al: Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 82:375-381, 2006 (Pubitemid 44223037)
21. Oton AB, Wang H, Leleu X, et al: Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 49:1738-1744, 2008
22. Elstrom RL, Andreadis C, Aqui NA, et al: Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6:569-576, 2006 (Pubitemid 43382145)
23. Jain AB, Marcos A, Pokharna R, et al: Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: Long-term experience from a single center. Transplantation 80:1692-1698, 2005 (Pubitemid 43053993)
24. Swerdlow SH CE, Harris NL: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. JASA 53:457-481, 1958
26. Cox DR: Regression models and life tables. J Royal Statist Soc (B) 34:187-220, 1972
27. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-723, 1958
28. Opelz G, Henderson R: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342:1514-1516, 1993 (Pubitemid 23362168)
29. Leblond V, Davi F, Charlotte F, et al: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 16:2052-2059, 1998 (Pubitemid 28265040)
30. Tsai DE, Hardy CL, Tomaszewski JE, et al: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 71:1076-1088, 2001 (Pubitemid 32448822)
31. Rees L, Thomas A, Amlot PL: Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression. Lancet 352:789, 1998 (Pubitemid 28404569)
32. Oertel SH, Verschuuren E, Reinke P, et al: Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 5:2901-2906, 2005 (Pubitemid 43923950)
33. Blaes AH, Peterson BA, Bartlett N, et al: Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: Results of a phase II trial. Cancer 104:1661-1667, 2005 (Pubitemid 41437429)
34. Choquet S, Trappe R, Leblond V, et al: CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 92:273-274, 2007 (Pubitemid 46852438)
35. Mamzer-Bruneel MF, Lome C, Morelon E, et al: Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 18:3622-3632, 2000
36. Maecker B, Jack T, Zimmermann M, et al: CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 25:4902-4908, 2007 (Pubitemid 350220420)
37. Caillard S, Lelong C, Pessione F, Moulin B: Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 6:2735-2742, 2006 (Pubitemid 44571695)
38. Choquet S, Mamzer BM, Hermine O, et al: Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 159:67-80, 2002
39. Muti G, Cantoni S, Oreste P, et al: Posttransplant lymphoproliferative disorders: Improved outcome after clinico-pathologically tailored treatment. Haematologica 87:67-77, 2002 (Pubitemid 34101115)
40. Webber SA, Naftel DC, Fricker FJ, et al: Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. Lancet 367:233-239, 2006 (Pubitemid 43107668)
41. Caillard S, Dharnidharka V, Agodoa L, et al: Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80: 1233-1243, 2005 (Pubitemid 41746802)
42. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International prognostic factors project on Advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
43. O'Brien S, Thomas D, Ravandi F, et al: Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113:3186-3191, 2008
44. Tsimberidou AM, Wen S, O'Brien S, et al: Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 25:4648-4656, 2007 (Pubitemid 350041550)